Role of angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias

Pharmacotherapy

Volumn 29, Issue 1, 2009, Pages 31-48

  Makkar, Kathy M ^a   Sanoski, Cynthia A ^b   Spinler, Sarah A ^c,d  

^a LANCASTER GENERAL HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Ace inhibitor; Aldosterone antagonist; Angiotensin ii receptor blocker; Angiotensin Converting enzyme inhibitor; ARB; Atrial fibrillation; Atrial fibrillation ablation; Ventricular arrhythmia; Ventricular tachycardia

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMILORIDE; AMIODARONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE TITRATION; FOLLOW UP; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SUDDEN DEATH; TREATMENT DURATION; TREATMENT RESPONSE;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION;

EID: 60149097009     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.1.31     Document Type: Review

References (60)

1. Fuster V, Rydén L, Cannom D, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006:114;257-354.
2. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993; 119:1187-97.
3. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41:2197-204.
4. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin- converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing- induced congestive heart failure. Circulation 2001; 104:2608-14.
5. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765-73.
6. Allessie M, Ausma J, Schotten U, et al. Electrical, contractile, and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54:230-46.
7. Frustaci A, Chimente C, Fulvio B, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-4.
8. Garg S, Narula J, Marelli C, et al. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias. Am J Cardiol 2006; 97:921-5.
9. Neuberger HR, Schotten U, Verheule S, et al. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005; 111:30-7.
10. Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:733-58.
11. Webster MW, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56:566-9.
12. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension 1998; 32:976-82.
13. Daleau P, Turgeon J. Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes. Pflugers Arch 1994; 427:553-5.
14. Boos CH, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation from pathophysiology to clinical trials. J Hum Hypertens 2005; 19:855-9.
15. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
16. Perrier E, Kerfant BG, Lalevee N, et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004; 110:776-83.
17. Vermes E, Tardif J, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insights from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2003; 107:2926-31.
18. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (Val-HeFT). Am Heart J 2005;149:548-57.
19. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program. Am HeartJ 2006; 152:86-92.
20. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glycerl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-22.
21. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86:527-32.
22. Pedersen OD, Bagger H, Kober L, Torp-Petersen C, on behalf of the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376-80.
23. Hansson L, Lindholm LH, Ekbom T, et al. Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP). Lancet 1999; 353:611-16.
24. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity-the Swedish trial in old patients with hypertension-2 (STOP-2) study. Lancet 1999; 354:1751-6.
25. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin receptor blockade: the VALUE trial. J Hypertens 2008; 26:403-11.
26. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998; 32:989-97.
27. Watchtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-19.
28. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. Circulation 2003; 18:684-90.
29. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the incidence of atrial fibrillation: results of the heart outcomes protection evaluation (HOPE) study. Am Heart J 2007; 154:448-53.
30. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population based cohort: the Framingham heart study. JAMA 1994; 271:840-4.
31. Anand K, Mooss AN, Hee TT, et al. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset AF. Am Heart J 2006; 152:217-22.
32. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008; 15:36-43.
33. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006; 46:21-8.
34. Shi Y, Tardif J C, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54:456-61.
35. Van Noord T, Crijns H, van den Berg MP, et al. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation [online exclusive article]. BMC Cardiovasc Disord 2005; 5:3. Available from http://www.biomedcentral.com/1471-2261/5/3.
36. Van Den Berg MP, Crijns HM, Van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1:355-63.
37. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331-6.
38. Ueng K, Tsai T, Yu W et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation. Eur Heart J 2003; 24: 2090-8.
39. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27:1841-6.
40. Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18:942-6.
41. Verma A, Wazni O, Marrouche N, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 2005; 45:285-92.
42. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:669-77.
43. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese cardiac study. Lancet 1995; 345:686-7.
44. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II). N Engl J Med 1992; 327:678-84.
45. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-6.
46. Ambrosioni E, Borghi C, Magnani B, et al, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332(2):80-5.
47. Budaj A, Cybulski J, Cedro K, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Eur HeartJ 1996; 17:1506-10.
48. Søgaard P, G0tzsche C, Ravkilde J, et al. Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction: effect on intervention with captopril. Circulation 1994; 90:101-7.
49. Fletcher RD, Cintron GB, Johnson G, et al. Enalapril decreases the prevalence of ventricular tachycardia in patients with chronic congestive heart failure. Circulation 1993; 87(suppl VI):VI49-55.
50. Pratt CM, Gardner M, Pepine C, et al, for the SOLVD Investigators. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. Am J Cardiol 1995; 75:1244-9.
51. Aronow WS, Mercando AD, Epstein S. Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. Am J Cardiol 1998; 81:1368-70.
52. Hattori Y, Atsushi S, Hiroaki F, et al. Effects of cilazapril on ventricular arrhythmia in patients with congestive heart failure. Clin Ther 1997; 19:481-6.
53. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000; 85:1207-11.
54. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-17.
55. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-21.
56. Teo KK, Mitchell B, Pogue J, et al. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high- risk individuals without heart failure or left ventricular dysfunction. Circulation 2004; 110:1413-17.
57. Cohn JN, Jonson G, Ziesche S, et al. A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 202-310.
58. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
59. U.S. National Institutes of Health. ClinicalTrials.gov. Available from http://clinicaltrials.gov/. Accessed July 22, 2008.
60. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ASC 2006 guidelines for the management of patients with ventricular arrhythmias and prevention of sudden cardiac death. J Am Coll Cardiol 2006; 48:1064-108.